title: Comparison of renal transplant outcome with Neoral versus Sandimmune as part of an initial triple therapy regimen.
authors.affiliation: Section of Transplantation Surgery, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
authors.forename: K
authors.initials: K
authors.lastname: alShaibani
authors.forename: S
authors.initials: S
authors.lastname: Raza
authors.forename: O
authors.initials: O
authors.lastname: alFurayh
authors.forename: K
authors.initials: K
authors.lastname: alMeshari
authors.forename: I
authors.initials: I
authors.lastname: alAhmadi
authors.forename: E
authors.initials: E
authors.lastname: alSabban
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001803:Blood Transfusion; D002102:Cadaver; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D004304:Dosage Forms; D004359:Drug Therapy, Combination; D004655:Emulsions; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D019520:Living Donors; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D004304:Dosage Forms; D004655:Emulsions; D016853:Muromonab-CD3; D016572:Cyclosporine